OBJECTIVES: Lenalidomide and dexamethasone (LenDex) is an active regimen for relapsed/refractory multiple myeloma (MM). However, there is limited data for the effect of LenDex on renal impairment (RI) and on renal reversibility. PATIENTS & METHODS: Fifty consecutive patients with relapsed/refractory MM received LenDex in 28-d cycles. Median lines of previous therapies were 2 (range: 1-6). Lenalidomide was administered on days 1-21 according to creatinine clearance (CrCl), while dexamethasone was given at a dose of 40 mg on days 1-4 and 15-18 for the first four cycles and only on days 1-4 thereafter. RESULTS: Twelve patients (24%) had RI at baseline, defined as CrCl < 50 mL/min. Most patients were pretreated with either thalidomide or bortezomib and > 50% of them were refractory to both drugs. At least partial response was documented in 60.5% and 58% of patients with and without RI. Median progression-free survival (PFS) and overall survival (OS) for all patients was 9 and 16 months, respectively. RI was not associated with an inferior PFS or OS. There were no differences in the incidence of adverse events among patients with and without RI. Three of 12 patients with RI (25%) achieved complete renal response and two (16%) achieved minor renal response with LenDex. CONCLUSIONS: We conclude that LenDex is an active treatment even in heavily pretreated MM. With dosing of lenalidomide according to renal function, LenDex can be administered to patients with RI (who may not have other treatment options) without excessive toxicity. Furthermore, LenDex may improve the renal function in approximately 40% of patients with RI.
OBJECTIVES:Lenalidomide and dexamethasone (LenDex) is an active regimen for relapsed/refractory multiple myeloma (MM). However, there is limited data for the effect of LenDex on renal impairment (RI) and on renal reversibility. PATIENTS & METHODS: Fifty consecutive patients with relapsed/refractory MM received LenDex in 28-d cycles. Median lines of previous therapies were 2 (range: 1-6). Lenalidomide was administered on days 1-21 according to creatinine clearance (CrCl), while dexamethasone was given at a dose of 40 mg on days 1-4 and 15-18 for the first four cycles and only on days 1-4 thereafter. RESULTS: Twelve patients (24%) had RI at baseline, defined as CrCl < 50 mL/min. Most patients were pretreated with either thalidomide or bortezomib and > 50% of them were refractory to both drugs. At least partial response was documented in 60.5% and 58% of patients with and without RI. Median progression-free survival (PFS) and overall survival (OS) for all patients was 9 and 16 months, respectively. RI was not associated with an inferior PFS or OS. There were no differences in the incidence of adverse events among patients with and without RI. Three of 12 patients with RI (25%) achieved complete renal response and two (16%) achieved minor renal response with LenDex. CONCLUSIONS: We conclude that LenDex is an active treatment even in heavily pretreated MM. With dosing of lenalidomide according to renal function, LenDex can be administered to patients with RI (who may not have other treatment options) without excessive toxicity. Furthermore, LenDex may improve the renal function in approximately 40% of patients with RI.
Authors: Meletios A Dimopoulos; Matthew C Cheung; Murielle Roussel; Ting Liu; Barbara Gamberi; Brigitte Kolb; H Guenter Derigs; HyeonSeok Eom; Karim Belhadj; Pascal Lenain; Richard Van der Jagt; Sophie Rigaudeau; Mamoun Dib; Rachel Hall; Henry Jardel; Arnaud Jaccard; Axel Tosikyan; Lionel Karlin; William Bensinger; Rik Schots; Nicolas Leupin; Guang Chen; Jennifer Marek; Annette Ervin-Haynes; Thierry Facon Journal: Haematologica Date: 2015-12-11 Impact factor: 9.941
Authors: Colin A Hutchison; Joan Bladé; Paul Cockwell; Mark Cook; Mark Drayson; Jean-Paul Fermand; Efstathios Kastritis; Robert Kyle; Nelson Leung; Sonia Pasquali; Christopher Winearls Journal: Nat Rev Nephrol Date: 2012-02-21 Impact factor: 28.314
Authors: I Breitkreutz; C Heiss; A Perne; J Beimler; D Jäger; G Egerer; A D Ho; K Neben; M Zeier; H Goldschmidt; M S Raab Journal: Bone Marrow Transplant Date: 2014-08-04 Impact factor: 5.483
Authors: Niels Wcj van de Donk; Güllü Görgün; Richard Wj Groen; Jana Jakubikova; Constantine S Mitsiades; Teru Hideshima; Jacob Laubach; Inger S Nijhof; Reinier A Raymakers; Henk M Lokhorst; Paul G Richardson; Kenneth C Anderson Journal: Cancer Manag Res Date: 2012-08-14 Impact factor: 3.989